resveratrol has been researched along with dabrafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachelot, L; Bessede, A; Boussemart, L; Corre, S; Denison, MS; Dumontet, E; Galibert, MD; Gautron, A; Gilot, D; Guillemin, GJ; Leclair, HM; Marine, JC; Mouchet, N; Perrot, A; Rambow, F; Rogiers, A; Soshilov, A; Tardif, N; Tarte, K | 1 |
| Li, H; Li, S; Li, TT; Liu, J; Lu, MD; Nie, JH; Wu, ML; Ye, HS | 1 |
2 other study(ies) available for resveratrol and dabrafenib
| Article | Year |
|---|---|
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imidazoles; MCF-7 Cells; Melanoma; Mice; Mice, SCID; Molecular Docking Simulation; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptors, Aryl Hydrocarbon; Resveratrol; Skin Neoplasms; Transcription Factors; Tumor Burden; Vemurafenib; Xenograft Model Antitumor Assays | 2018 |
Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.
Topics: Humans; Mutation; Proto-Oncogene Proteins B-raf; Resveratrol; Signal Transduction; STAT3 Transcription Factor; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2022 |